FDA rejects Akcea rare-disease drug that uses gene-blocking technology
The FDA on Monday rejected Akcea Therapeutics' application to market Waylivra, its drug for familial chylomicronemia syndrome.
The Food and Drug Administration on Monday rejected Akcea Therapeutics’ application to market Waylivra, its drug for familial chylomicronemia syndrome, in the United States.
Akcea didn’t give a reason for the rejection. Waylivra, also known as volanesorsen, would have been Akcea’s
